Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1997-06-10
1998-12-22
McKane, Joseph K.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
548491, 548492, A61K 3140, C07D20910
Patent
active
058520465
ABSTRACT:
Benzo-fused heterocyclic compounds having a 5-membered ring, processes for their preperation, their use as medicaments, their use as diagnostic agents and medicaments containing them.
Benzo-fused heterocyclic compounds having a 5-membered ring, of the formula I ##STR1## where X is N or CR(6); Y is oxygen, S or NR(7); A and B together are a bond or are both hydrogen, if, at the same time, X is CR(6) and Y is NR(7),
one of the substituents R(1) to R(6) is a --CO--N.dbd.C(NH.sub.2).sub.2 group;
the other respective substituents R(1) to R(6) are H, Hal or alkyl;
up to two of the other substituents R(1) to R(6) are CN, NO.sub.2, N.sub.3, (C.sub.1 -C.sub.4)-alkoxy, CF.sub.3 ; up to one of the other substituents is R(8)--C.sub.n H.sub.2n --Z-- or phenyl;
R(7) is H, alk(en)yl or R(8)--C.sub.n H.sub.2n --, and pharmaceutically tolerated salts there of, are described.
A process f or the preparation of the compounds I which comprises reacting a compound of the formula II ##STR2## in which one of the substituents R(1)' to R(5)' is a --CO--L group and L is a leaving group which can easily be replaced nucleophilically, with guanidine, and, if appropriate, converting the product into the pharmacologically tolerated salt, furthermore is also described.
REFERENCES:
patent: 3780027 (1973-12-01), Cragoe et al.
patent: 4814345 (1989-03-01), Ohlendorf et al.
patent: 5091394 (1992-02-01), Englert et al.
patent: 5292755 (1994-03-01), Englert et al.
Scholz et al., "Na.sup.+ /H.sup.+ Exchange and its Inhibition in Cardiac Ischemia and Reperfusion," Basic Res. Cardiol., 88:443-455 (1993).
Scholz et al., "Hoe 694, a New Na.sup.+ /H.sup.+ Exchange Inhibitor and its Effects in Cardiac Ischaemia," Br. J. Pharmacol., 109:562-568 (1993).
Hendrikx et al., "New Na.sup.+ /H.sup.+ Exchange Inhibitor HOE 694 Improves Postischemic Function and High-Energy Phospate Resynthesis and Reduces Ca.sup.2+ Overload in Isolated Perfused Rabbit Heart," Circulation, 89(6):2787-2798 (1994).
L'Allemain et al., "Blockade of the Na.sup.+ /H.sup.+ Antiport Abolishes Growth Factor-Induced DNA Synthesis in Fibroblasts," J. Biol. Chem., 259(7):4313-4319 (1984).
Ghigo et al., "Evidence for a Role of the Na.sup.+ /H.sup.+ Exchanger in the Colony-Stimulating-Factor-Induced Ornithine Decarboxylase Activity and Proliferation of the Human Cell Line M-07e," J. Cell. Physiol., 145:147-154(1990).
Lyons et al., "Enhancement of Hyperthermia Effect in Vivo by Amiloride and DIDS," Int. J. Radiation Oncology Biol. Phys., 25:95-103 (1992).
Maidorn et al., "Therapeutic Potential of Analogues of Amiloride: Inhibition of the Regulation of Intracellular pH as a Possible Mechanism of Tumour Selective Therapy," Br. J. Cancer, 67:297-303 (1993).
Ng et al., "Leucocyte Na.sup.+ /H.sup.+ Antiport Activity in Type 1 (Insulin-Dependent) Diabetic Patients With Nephropathy," Diabetologia, 33:371-377 (1990).
Song et al., "Thermosensitization by Lowering Intracellular pH with 5-(N-ethyl-N-isopropyl) Amiloride," Radiotherapy and Oncology, 27:252-258 (1993).
Albus Udo
Crause Peter
Lang Hans-Jochen
Scholz Wolfgang
Schwark Jan-Robert
Hoechst Aktiengesellschaft
McKane Joseph K.
LandOfFree
Benzo-fused heterocyclic compounds having a 5-membered ring proc does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Benzo-fused heterocyclic compounds having a 5-membered ring proc, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Benzo-fused heterocyclic compounds having a 5-membered ring proc will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2048082